Centers | ||
Therapeutic Accelerator Program (TAP) | Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) | Presude Life Sciences |
Test |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Brigham & Woman's Hospital and Sanofi to Partner in Type 1 Diabetes SpaceSanofi and Brigham & Woman's Hospital an affiliate of Harvard University have entered into a joint collaboration to develop new drugs based on novel immunomodulatory approach to treat Type 1 Diabetes. Scientists from both groups will be... View all Evotec and Yale University form Open Innovation AllianceEvotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially,... View all |
No EVENTS for listing |
No Job Posts |


